Li Ziyun, Zhang Li, Wan Zhenxia, Liu Huijuan, Zhang Ting, Li Yan
Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.
Front Microbiol. 2025 Sep 11;16:1618892. doi: 10.3389/fmicb.2025.1618892. eCollection 2025.
The gut microbiota, as a critical guardian of human health, maintains physiological homeostasis, modulating immunity, and facilitates nutrient metabolism. , a probiotic gut commensal, has garnered increasing scientific attention. This review systematically examines its biological characteristics, then analyzes mechanisms promoting health (immunomodulation, metabolic regulation, and intestinal barrier reinforcement), and finally evaluates disease associations (metabolic disorders, neurological diseases, inflammatory conditions, and malignancies). Current evidence shows that therapeutic efficacy against obesity, non-alcoholic fatty liver disease, inflammatory bowel disease, autism spectrum disorder, and colorectal cancer via short-chain fatty acids secretion, bile acid transformation, and host immunity modulation. Dietary factors (e.g., inulin), pharmacological agents (e.g., metformin, aspirin), and lifestyle interventions (e.g., exercise synbiotics) dynamically regulate its abundance, underscoring therapeutic potential. Despite translational challenges-like optimizing cultivation, dose-response characterization, and genetic tool development-emerging applications (engineered probiotics, fecal microbiota transplantation, and synthetic biology) highlight broad prospects. Future research should prioritize context-dependent mechanisms across diseases and refined translation strategies for microbiome-based precision medicine.
肠道微生物群作为人类健康的关键守护者,维持生理稳态,调节免疫,并促进营养代谢。作为一种共生的益生菌,已越来越受到科学界的关注。本综述系统地研究了其生物学特性,然后分析了促进健康的机制(免疫调节、代谢调节和肠道屏障增强),最后评估了与疾病的关联(代谢紊乱、神经疾病、炎症性疾病和恶性肿瘤)。目前的证据表明,通过分泌短链脂肪酸、转化胆汁酸和调节宿主免疫,对肥胖、非酒精性脂肪性肝病、炎症性肠病、自闭症谱系障碍和结直肠癌具有治疗效果。饮食因素(如菊粉)、药物制剂(如二甲双胍、阿司匹林)和生活方式干预(如运动合生元)可动态调节其丰度,凸显了其治疗潜力。尽管存在转化挑战,如优化培养、剂量反应表征和基因工具开发,但新兴应用(工程益生菌、粪便微生物群移植和合成生物学)前景广阔。未来的研究应优先关注不同疾病中依赖于背景的机制,以及基于微生物组的精准医学的精细转化策略。